Curium struck a definitive agreement to acquire Lantheus in a deal valued up to roughly $8 billion, aiming to combine Curium’s theranostics manufacturing network with Lantheus’ U.S. radiodiagnostics franchise. Lantheus shareholders are set to receive $102.50 per share in cash at closing, plus contingent value rights tied to sales milestones through 2030. The companies expect to close in the first half of 2027, subject to approvals. Lantheus is slated to suspend 2026 guidance ahead of a scheduled earnings release, reflecting the transaction’s timing and regulatory path. If completed, the merged company would broaden coverage across nuclear medicine—moving from isotope production through diagnostic imaging and targeted radionuclide therapy—across oncology, neurology, and cardiology footprints in more than 70 countries.